Jessie Xu is a partner in the Corporate team of our Shanghai office. She provides comprehensive legal services for various offshore transactions, covering initial public offerings and secondary offerings (including listings of SPACs), mergers and acquisitions involving both private and listed companies (including privatisation deals and De-SPAC transactions), joint ventures, equity financing, banking and finance, group restructuring, funds, and trusts. She has handled numerous high-end cross-border transactions across diverse sectors such as biopharmaceuticals, artificial intelligence, communications, education, telecommunications and m
...Jessie Xu is a partner in the Corporate team of our Shanghai office. She provides comprehensive legal services for various offshore transactions, covering initial public offerings and secondary offerings (including listings of SPACs), mergers and acquisitions involving both private and listed companies (including privatisation deals and De-SPAC transactions), joint ventures, equity financing, banking and finance, group restructuring, funds, and trusts. She has handled numerous high-end cross-border transactions across diverse sectors such as biopharmaceuticals, artificial intelligence, communications, education, telecommunications and media, energy, infrastructure, and real estate.
Jessie has spearheaded several significant offshore projects. She advised on DualityBio's HK$1.64 billion listing on the Hong Kong Stock Exchange (HKEX) and Haitian’s HK$10.1 billion listing on the HKEX, both of which won 2025 China Business Law Journal (CBLJ) Deal of the Year awards. She also represented China Resources Beverage in its listing on the Main Board of the HKEX, which secured a 2024 CBLJ Deal of the Year award and was shortlisted for a 2025 Deal of the Year award at the ALB China Law Awards. In the debt capital markets space, she advised Cinda Management on its issue of notes under its US$5 billion programme.
In addition, she acted for Gracell in AstraZeneca’s acquisition of Gracell Biotechnologies, which won a 2024 CBLJ Deal of the Year award and an M&A Deal of the Year award at the 2024 ALB China Law Awards. Earlier in her career, she represented XPeng Inc. in the listing of its Class A ordinary shares in the form of American Depositary Shares on the New York Stock Exchange, which CBLJ awarded a 2020 Deal of the Year award.
Among the honours Jessie has received are: The A - List 2025-26: Rising Stars of China Business Law Journal, CBLJ, “Prominent Legal Practitioners (Capital Markets) at the 2025 LegalOne Yangtze River Delta Law Awards,” “ALB Offshore Client Choice 2025,” and “ALB China Top 15 Rising Lawyers in 2023”.
Jessie does not practise PRC law. She is fluent in Mandarin and English.
